Folate vs Folic Acid: Why the Difference Matters for Your Health

Vitamin B9's biological activity operates through a family of compounds collectively called folates, all of which must be converted to the active coenzyme form 5-methyltetrahydrofolate (5-MTHF) to participate in metabolism. 5-MTHF serves as the methyl donor for the conversion of homocysteine to methionine, a reaction catalysed by methionine synthase and requiring vitamin B12 as a cofactor. This regeneration of methionine is critical for two reasons: it prevents homocysteine accumulation (elevated homocysteine is a cardiovascular risk factor and a marker of impaired one-carbon metabolism) and it produces S-adenosylmethionine (SAM), which donates methyl groups to hundreds of reactions including DNA methylation, histone modification, and neurotransmitter synthesis. Folate-derived tetrahydrofolate (THF) is also essential for the synthesis of thymidylate — a component unique to DNA — and purines needed for both DNA and RNA. These roles explain why folate deficiency disproportionately affects rapidly dividing cells: developing embryos, haematopoietic (blood-forming) cells, and intestinal epithelial cells are all highly sensitive to folate insufficiency. In the developing embryo, the neural tube — the precursor of the brain and spinal cord — closes within 28 days of conception, a period during which most women do not yet know they are pregnant. Insufficient folate during this critical window is the primary cause of neural tube defects including spina bifida and anencephaly. Folate also contributes to the regulation of epigenetic marks across the genome, potentially influencing disease risk across generations.

Folic acid, the fully oxidised synthetic form of vitamin B9, must undergo multi-step enzymatic reduction before it can enter the active folate pool. The first step — conversion to dihydrofolate — occurs readily, but the subsequent conversion to tetrahydrofolate and then to 5-MTHF requires the enzyme dihydrofolate reductase (DHFR) and then methylenetetrahydrofolate reductase (MTHFR). The capacity of DHFR in humans is limited and saturable: studies suggest that doses of folic acid above approximately 200–266mcg may exceed the immediate processing capacity of the gut mucosa, leading to unmetabolised folic acid (UMFA) appearing in circulation. The health significance of UMFA is actively debated — it may interfere with folate receptor binding, impair natural killer cell function, and mask B12 deficiency — though the clinical consequences at commonly consumed doses remain uncertain. By contrast, naturally occurring food folate (primarily as 5-methyltetrahydrofolate and other reduced forms) and the commercially available supplement form methylfolate (5-MTHF) can enter the active folate cycle directly without requiring the MTHFR step. This distinction becomes particularly important in the context of MTHFR genetic variants, discussed below. From a regulatory standpoint, folic acid has approximately 1.7 times the bioavailability of food folate when both are consumed with food; this is why dietary folate equivalents (DFEs) use a conversion factor: 1 DFE equals 1mcg food folate, 0.6mcg folic acid taken with food, or 0.5mcg supplemental folic acid taken on an empty stomach.

The MTHFR gene encodes the enzyme methylenetetrahydrofolate reductase, which catalyses the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate — the primary circulating form of folate and the direct methyl donor for homocysteine remethylation. Two common genetic variants in this gene — C677T and A1298C — reduce enzyme activity. The C677T variant is the more clinically significant: individuals who inherit one copy (heterozygous) have approximately 35% reduced MTHFR activity, while those who inherit two copies (homozygous, denoted TT genotype) have around 70% reduced activity. The C677T variant has a population frequency that varies by ethnicity: homozygosity affects approximately 8–12% of Northern Europeans, 10–15% of Americans, and up to 25% of some Hispanic populations. People with the TT genotype tend to have higher blood homocysteine levels and lower circulating 5-MTHF, which may increase risk of cardiovascular disease, recurrent miscarriage, neural tube defects in offspring, depression, and impaired methylation capacity. The clinical relevance of heterozygous MTHFR variants is less clear and likely only significant when dietary folate intake is suboptimal. For those with the homozygous TT genotype, supplementing with 5-MTHF (methylfolate) rather than folic acid is a logical choice because it bypasses the impaired enzymatic step entirely — though randomised trial evidence for clinical superiority over standard folic acid at adequate doses is not yet conclusive. Testing for MTHFR variants is available through standard genetic testing services and is increasingly ordered by functional medicine practitioners.

The word folate itself derives from the Latin folium, meaning leaf, reflecting the fact that dark green leafy vegetables are the most concentrated food source of naturally occurring folate. Cooked spinach tops the list at approximately 263mcg DFE per 180g serving, followed closely by boiled lentils at 358mcg per cooked cup — making lentils one of the single richest folate sources available. Other legumes including black beans, chickpeas, kidney beans, and peas each provide 130–294mcg per cooked cup, making regular consumption of pulses one of the most effective dietary strategies for meeting folate needs. Asparagus provides around 134mcg per 90g serving, broccoli approximately 104mcg per 90g serving, and Brussels sprouts around 78mcg per 90g serving. Avocado is an unusually folate-rich fruit at around 122mcg per half fruit. Beetroot provides approximately 68mcg per 100g cooked. Citrus fruits — particularly orange juice — contribute meaningful amounts, with a glass of freshly squeezed orange juice providing around 75mcg. Liver is an exceptionally rich animal source at approximately 215mcg per 75g serving. Fortified breakfast cereals and breads contribute substantially to population folate intake in countries with mandatory fortification programmes — the US, Canada, Australia, and many others have required folic acid fortification of wheat flour since the late 1990s, significantly reducing rates of neural tube defects. Food folate is heat-sensitive and water-soluble: cooking methods that minimise water contact and heat exposure — steaming rather than boiling, using cooking water in sauces — preserve more folate.

The evidence linking folate status to neural tube defect prevention is among the most robust in nutritional epidemiology. The landmark MRC Vitamin Study, published in 1991, demonstrated that supplementation with 4mg of folic acid in women at high risk of neural tube defect recurrence reduced incidence by 72%. Subsequent studies in general populations confirmed that daily supplementation with 400mcg reduces the risk of first-time neural tube defects by approximately 50–70%. Because neural tube closure is complete by day 28 of embryonic development — before most women realise they are pregnant — current guidelines in most countries recommend that all women who could become pregnant take 400mcg of folic acid daily, or consume equivalent amounts through fortified foods. Women with a previous neural tube defect-affected pregnancy, those with the MTHFR TT genotype, those taking anti-epileptic medications that interfere with folate metabolism, or those with diabetes or obesity are typically recommended higher doses of 4–5mg daily under medical supervision. Beyond neural tube defects, higher folate intake during pregnancy is associated with reduced risks of cleft palate, congenital heart defects, and preterm birth in observational studies. Adequate folate also supports placental development and the extraordinary cell division demands of the first trimester. Some researchers argue that the current population recommendation of 400mcg may be insufficient for women with impaired folate metabolism and that 5-MTHF at comparable doses may be a more appropriate universal recommendation, particularly given the MTHFR variant prevalence. This remains an area of active scientific debate.

The supplement market offers several forms of vitamin B9: folic acid (the conventional synthetic form), folinic acid (5-formyltetrahydrofolate, also called leucovorin), and methylfolate (5-methyltetrahydrofolate or 5-MTHF), the latter sold under brand names including Metafolin and Quatrefolic. For the general population without known MTHFR variants, standard folic acid at 400mcg daily remains the evidence-based recommendation during reproductive years, supported by decades of safety and efficacy data. Concerns about UMFA at this dose are theoretically plausible but not yet demonstrated to cause measurable harm in most people. For those with MTHFR C677T homozygosity or with a personal or family history of neural tube defects, methylfolate (5-MTHF) is a logical choice: it bypasses the rate-limiting enzymatic step, does not produce UMFA, and is available in supplements ranging from 400mcg to 15mg. Starting at standard doses (400–800mcg) and increasing only under guidance is prudent, as some people with severely impaired methylation report paradoxical reactions to high-dose methylfolate. Folinic acid is sometimes used as an intermediate option for those who react to methylfolate. B-complex supplements typically provide folic acid; those wishing to switch to methylfolate need to specifically seek formulations listing 5-MTHF or methylfolate. For most people eating diets rich in legumes, leafy greens, and fortified foods, supplementation may be unnecessary outside pregnancy and conception planning — but given the prevalence of suboptimal intake in Western diets, a standard multivitamin containing 400mcg of folate is a reasonable low-risk insurance policy for most adults.